Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry
| العنوان: | Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry |
|---|---|
| المؤلفون: | Diederik M. Somford, Reindert J.A. van Moorselaar, Carin A. Uyl-de Groot, Ronald de Wit, Laurent M.C.L. Fossion, Niven Mehra, Hans M. Westgeest, Addy C. M. van de Luijtgaarden, Juleon L.L.M. Coenen, N.I. Weijl, Maud M. Geenen, Winald R. Gerritsen, Agnes J. van de Wouw, A.C.M. van den Bergh, Mathijs P. Hendriks, Marco B. Polee, Alphonsus J. M. van den Eertwegh, Andre M. Bergman, Malou C.P. Kuppen, Inge M. van Oort, Daan ten Bokkel Huinink |
| المساهمون: | Guided Treatment in Optimal Selected Cancer Patients (GUTS), Health Technology Assessment (HTA), Medical oncology, Urology, CCA - Cancer Treatment and quality of life, Internal medicine |
| المصدر: | European urology oncology, 4(4), 618-627. De Tijdstroom/Elsevier European Urology Oncology, 4, 618-627 European urology oncology, 4, 618-627. Elsevier Kuppen, M C P, Westgeest, H M, van den Eertwegh, A J M, van Moorselaar, R J A, van Oort, I M, Coenen, J L L M, van den Bergh, A C M F, Mehra, N, Somford, D M, Bergman, A M, Ten Bokkel Huinink, D, Fossion, L, Geenen, M M, Hendriks, M P, van de Luijtgaarden, A C M, Polee, M B, Weijl, N I, van de Wouw, A J, de Wit, R, Uyl-de Groot, C A & Gerritsen, W R 2021, ' Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer : Results from the Dutch Castration-resistant Prostate Cancer Registry ', European Urology Oncology, vol. 4, no. 4, pp. 618-627 . https://doi.org/10.1016/j.euo.2019.09.005 European Urology Oncology, 4, 4, pp. 618-627 European Urology Oncology, 4(4), 618-627. Elsevier BV |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Oncology, Male, ANTITUMOR-ACTIVITY, 030232 urology & nephrology, chemistry.chemical_compound, Prostate cancer, 0302 clinical medicine, Prednisone, Medicine, Sequencing, Registries, Castration-resistant prostate cancer, DOCETAXEL, Abiraterone acetate, TIME, Prostatic Neoplasms, Castration-Resistant, TRIALS, Docetaxel, Pharmaceutical Preparations, Cabazitaxel, 030220 oncology & carcinogenesis, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Androgens, Cross resistance, medicine.drug, medicine.medical_specialty, CLINICAL-OUTCOMES, ENZALUTAMIDE, Urology, INCREASED SURVIVAL, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, Antigen, SDG 3 - Good Health and Well-being, Internal medicine, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], Enzalutamide, Humans, Radiology, Nuclear Medicine and imaging, Real-world outcomes, Retrospective Studies, Androgen-receptor targeting agents, business.industry, Androgen Antagonists, medicine.disease, Androgen receptor, chemistry, Surgery, business |
| الوصف: | Background: Cross resistance between androgen-receptor targeting therapies (ARTs) (abiraterone acetate plus prednisone [ABI + P] or enzalutamide [ENZ]) for treatment of metastatic castration-resistant prostate cancer (mCRPC) may affect responses to second ART (ART2).Objective: To establish treatment duration and prostate-specific antigen (PSA) response of ART2 in real-world mCRPC patients treated with or without other life-prolonging drugs (LPDs; ie, docetaxel, cabazitaxel, or radium-223) between ART1 and ART2.Design, Setting, and participants: Castration-resistant prostate cancer patients, diagnosed between 2010 and 2016 were retrospectively registered in Castration-resistant Prostate Cancer Registry (CAPRI). Patients treated with both ARTs were clustered into two subgroups: ART1 > ART2 or ART1 > LPD > ART2.Outcome measurements and statistical analysis: Outcomes were >= 50% PSA re- sponse and treatment duration of ART2. Descriptive statistics and binary logistic regression after multiple imputations were performed.Results and limitations: A total of 273 patients were included with a median follow-up of 8.4 mo from ART2. Patients with ART1 > ART2 were older and had favourable prognostic characteristics at ART2 baseline compared with patients with ART1 > LPD > ART2. No differences between ART1 > ART2 and ART1 > LPD > ART2 were found in PSA response and treatment duration. Multivariate analysis suggested that PSA response of ART2 was less likely in patients with visceral metastases (odds ratio [OR] 0.143, p = 0.04) and more likely in patients with a relatively longer duration of androgen-deprivation treatment (OR 1.028, p = 0.01) and with ABI + P before ENZ (OR 3.192, p = 0.02). A major limitation of this study was missing data, a common problem in retrospective observational research.Conclusion: The effect of ART2 seems to be low, with a low PSA response rate and a short treatment duration irrespective of interposed chemotherapy or radium-223, especially in patients with short time on castration, visceral disease, and ENZ before ABI + P.Patient summary: We observed no differences in outcomes of patients treated with sequential abiraterone acetate plus prednisone (ABI + P) and enzalutamide (ENZ) with or without interposed chemotherapy or radium-223. In general, outcomes were lower than those in randomised trials, questioning the additional effect of second treatment with ABI + P or ENZ in daily practice. (C) 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2588-9311 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5688ade1d20f2f2f131d73a057ff810 https://research.rug.nl/en/publications/41b16b5e-d8f6-46e7-904f-77d48f068028 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....c5688ade1d20f2f2f131d73a057ff810 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 25889311 |
|---|